- Home
- Publications
- Publication Search
- Publication Details
Title
Angiogenesis inhibitors in early development for gastric cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 26, Issue 9, Pages 1007-1017
Publisher
Informa UK Limited
Online
2017-08-03
DOI
10.1080/13543784.2017.1361926
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
- (2017) Salah-Eddin Al-Batran et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.
- (2017) Yoon-Koo Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)
- (2017) Charles S. Fuchs et al. JOURNAL OF CLINICAL ONCOLOGY
- Antiangiogenic therapies in gastric cancer: trusting the pathway
- (2016) M. Alsina et al. ANNALS OF ONCOLOGY
- Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial
- (2016) H. H. Yoon et al. ANNALS OF ONCOLOGY
- Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
- (2016) Markus Moehler et al. BMC CANCER
- Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial
- (2016) Ulrich T Hacker et al. BRITISH JOURNAL OF CANCER
- Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma
- (2016) Camillo Porta et al. EUROPEAN UROLOGY
- Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA).
- (2016) Peter C. Enzinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
- (2016) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial
- (2016) Nick Pavlakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
- (2016) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Encouraging results for PD-1 inhibition in gastric cancer
- (2016) Elizabeth C Smyth et al. LANCET ONCOLOGY
- Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
- (2016) Seung Tae Kim et al. Oncotarget
- VEGF and Intraocular Neovascularization: From Discovery to Therapy
- (2016) Napoleone Ferrara Translational Vision Science & Technology
- Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
- (2015) E. G. Chiorean et al. ANNALS OF ONCOLOGY
- CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer
- (2015) Martin Turcotte et al. CANCER RESEARCH
- Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors
- (2015) Cariad Chester et al. CURRENT OPINION IN IMMUNOLOGY
- Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study
- (2015) Didier Meulendijks et al. INVESTIGATIONAL NEW DRUGS
- Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study
- (2015) Michael B. Atkins et al. JOURNAL OF CLINICAL ONCOLOGY
- The twisted survivin connection to angiogenesis
- (2015) C. Sanhueza et al. Molecular Cancer
- Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer
- (2015) Do-Youn Oh et al. Cancer Research and Treatment
- Enhancement of T cell recruitment and infiltration into tumours
- (2014) C. Oelkrug et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer
- (2014) Marcelo Garrido et al. Expert Review of Anticancer Therapy
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
- (2014) Bradley J Monk et al. LANCET ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification
- (2014) S. T. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Targeting receptor tyrosine kinases in gastric cancer
- (2014) Asahiro Morishita WORLD JOURNAL OF GASTROENTEROLOGY
- T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy
- (2014) I. Melero et al. Cancer Discovery
- Prognostic Value of Vascular Endothelial Growth Factor Expression in Resected Gastric Cancer
- (2013) Lei Liu et al. Asian Pacific Journal of Cancer Prevention
- Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effectin vivo
- (2013) S. Yasuda et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
- (2013) L. Xie et al. CLINICAL CANCER RESEARCH
- Geographic differences in approach to advanced gastric cancer: Is there a standard approach?
- (2013) Richard Kim et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil
- (2013) Zhengdeng Lei et al. GASTROENTEROLOGY
- Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study
- (2013) M. Martin-Richard et al. INVESTIGATIONAL NEW DRUGS
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
- (2013) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
- (2013) Hugo E R Ford et al. LANCET ONCOLOGY
- Predicting the Effects of Anti-angiogenic Agents Targeting Specific VEGF Isoforms
- (2012) Stacey D. Finley et al. AAPS Journal
- Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma
- (2012) Martina Mayr et al. BMC CANCER
- Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
- (2012) D H Yoon et al. BRITISH JOURNAL OF CANCER
- The balance of proangiogenic and antiangiogenic VEGFA isoforms regulate follicle development
- (2012) Renee M. McFee et al. CELL AND TISSUE RESEARCH
- Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
- (2012) Jung Hun Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis
- (2012) Ling Peng et al. MOLECULAR BIOLOGY REPORTS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Inhibition of Prostate Cancer Osteoblastic Progression with VEGF121/rGel, a Single Agent Targeting Osteoblasts, Osteoclasts, and Tumor Neovasculature
- (2011) K. A. Mohamedali et al. CLINICAL CANCER RESEARCH
- Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis
- (2011) C. Lieu et al. CLINICAL CANCER RESEARCH
- Esophagogastric Cancer: Integration of Targeted Therapies into Systemic Chemotherapy
- (2011) M. Moehler et al. CURRENT CANCER DRUG TARGETS
- Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2011) Peter C. Thuss-Patience et al. EUROPEAN JOURNAL OF CANCER
- mTOR as a therapeutic target in patients with gastric cancer
- (2011) Salah-Eddin Al-Batran et al. INTERNATIONAL JOURNAL OF CANCER
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Angiogenesis in Esophagogastric Adenocarcinoma
- (2011) A. F. C. Okines et al. ONCOLOGIST
- PI3K/AKT/mTOR Pathway in Angiogenesis
- (2011) Jayashree Karar et al. Frontiers in Molecular Neuroscience
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
- (2010) SaeGwang Park et al. CANCER CELL
- The Clinicopathological Significance of Tissue Levels of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor in Gastric Cancer
- (2010) Seong-Eun Kim et al. Gut and Liver
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The use of thalidomide in the management of bleeding from a gastric cancer
- (2009) K Lambert et al. PALLIATIVE MEDICINE
- Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation
- (2009) C. Therapontos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started